Clinical Effectiveness of Liraglutide in Type 2 Di

Authors: Amrita Ostawal Emina Mocevic Nana Kragh Weiwei Xu

Publish Date: 2016/06/27

Volume: 7, Issue: 3, Pages: 411-438

PDF Link

Abstract

In clinical trials liraglutide has proven to be an effective drug for the treatment of type 2 diabetes mellitus T2DM The realworld effectiveness of liraglutide has been investigated in numerous studies The aim of this systematic literature review is to collate evidence on the realworld clinical effectiveness of liraglutideA review of publications from Medline EMBASE the Cochrane Library and conference proceedings was conducted to identify observational studies that assessed the clinical effectiveness of liraglutide in realworld clinical practice This review was conducted according to the National Institute of Health and Care Excellence NICE guidance No language or time limits were applied except to the conference proceedings 2013–2015 Endpoints for data extraction were decided a priori Study quality appraisal was done for fulltext journal articlesOf 124 publications included in the review 43 were fulltext articles Liraglutide significantly reduces glycated hemoglobin HbA1c within 6 months of initiating treatment mean change in HbA1c from baseline −09 to −22 HbA1c 70 295–650 The NICE composite endpoint HbA1c reduction ≥1 and weight reduction ≥3 was met in 169–470 of patients with liraglutide treatment Liraglutide therapy led to a mean change in absolute weight from baseline of −13 to −865 kg Liraglutide treatment was well tolerated in patients with T2DM The rate of occurrence of hypoglycemia with liraglutide monotherapy was ≤08 Hypoglycemia was more common in patients taking antidiabetic medications 00–152 together with liraglutide The beneficial glycemic and weight effect of liraglutide therapy in patients with T2DM was maintained for at least 12 monthsEvidence from observational studies reflecting realworld clinical practice demonstrates that liraglutide therapy improves glycemic control with a low risk of hypoglycemia and is associated with significant weight loss in patients with T2DM These observations are consistent with clinical trial findingsType 2 diabetes mellitus T2DM is a chronic metabolic disorder characterized by increased blood glucose levels ie hyperglycemia which over time can cause microvascular and macrovascular complications 1 The main goal of T2DM treatment is to achieve and maintain patients’ individual target blood glucose levels thus reducing the occurrence of complications 2

Keywords: